Head-to-head comparison
| Property | Mazdutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | 6.1-28.1 days (Tmax ~72 hours); extended half-life supports once-weekly dosing | ~5 days |
| Mol. Weight | — | 4,813.45 Da |
| Side Effects | Nausea, Diarrhea, Vomiting | Nausea (up to 31%), Diarrhea, Vomiting |
Key differences
- Receptor targets: Tirzepatide activates GLP-1 and GIP receptors; mazdutide activates GLP-1 and glucagon receptors. Both share GLP-1-mediated appetite suppression, but their second receptor pathways are metabolically distinct.
- Hepatic effects: Mazdutide's glucagon agonism directly stimulates hepatic fatty acid oxidation and FGF21 secretion, producing up to 80% liver fat reduction in Phase 2 data; tirzepatide's GIP agonism improves insulin sensitivity and fat metabolism but lacks direct hepatic lipid-clearing activity.
- Efficacy: Tirzepatide SURMOUNT trials demonstrated 22.5% weight loss at 15 mg over 72 weeks; mazdutide Phase 2 showed 14.8% at 6 mg over 48 weeks, though Phase 3 data may narrow or widen this gap.
- Regulatory status: Tirzepatide is FDA-approved as Mounjaro (T2D) and Zepbound (obesity); mazdutide is approved only in China as Xinermei and is in US Phase 2 trials.
- Dosing: Both are once-weekly subcutaneous injections. Tirzepatide titrates from 2.5 to 15 mg; mazdutide Phase 2 used 3 to 6 mg weekly.
- Energy expenditure: Mazdutide's glucagon component increases energy expenditure through thermogenesis and FGF21 signaling, producing weight loss through both reduced intake and increased energy burning; tirzepatide's weight loss is driven primarily by appetite suppression and improved insulin sensitivity.
- Side effects: Both cause GLP-1-class GI effects. Tirzepatide reports nausea in up to 31% of patients. Mazdutide's side effect profile is consistent with the GLP-1 class, with the added theoretical risk of glucagon-mediated hyperglycemia (counterbalanced by GLP-1 effects in trial data).
The verdict
Tirzepatide has demonstrated greater overall weight loss in larger, more mature clinical trials and is FDA-approved. Mazdutide's distinct advantage is its glucagon-mediated hepatic fat clearance, which makes it potentially more relevant for patients with MASLD/MASH where liver fat reduction is a primary treatment goal. These are complementary rather than directly competing approaches: tirzepatide optimizes insulin sensitization and maximal weight loss, while mazdutide targets the liver-obesity axis. Head-to-head data does not yet exist.
Frequently asked questions
Both are dual-receptor agonists, but they target different second receptors alongside GLP-1. Tirzepatide adds GIP agonism, which enhances insulin sensitivity and potentiates the GLP-1 weight loss effect. Mazdutide adds glucagon agonism, which increases hepatic fatty acid oxidation and energy expenditure. The metabolic profiles are meaningfully different.
Mazdutide has a mechanistic advantage for fatty liver disease. Its glucagon receptor activation directly stimulates hepatic lipid clearance and FGF21 secretion, showing up to 80% liver fat reduction in Phase 2 data. Tirzepatide reduces liver fat secondarily through weight loss and insulin sensitization but does not have direct hepatic lipid-clearing activity.
Based on available data, tirzepatide has demonstrated greater weight loss: 22.5% in SURMOUNT-1 versus mazdutide's 14.8% in Phase 2. However, direct comparison is limited because mazdutide Phase 2 data comes from a smaller trial in Chinese adults with shorter duration and lower doses. Phase 3 mazdutide results may change this picture.
Mazdutide is approved in China as Xinermei for obesity and type 2 diabetes. Outside China, it is in Phase 2 clinical trials in the United States. There is no prescription, compounding, or research chemical access pathway in Western markets. Tirzepatide is available by prescription in the US, EU, and other markets.
Both share GLP-1-class GI side effects including nausea, vomiting, diarrhea, and decreased appetite. Tirzepatide also reports injection site reactions and nausea rates up to 31%. Mazdutide's glucagon component introduces a theoretical risk of hyperglycemia, though this has been offset by GLP-1-mediated insulin secretion in published trials.